share_log

CRISPR Therapeutics Shares Are Trading Higher After the Company and Vertex Pharmaceuticals Announced the FDA Granted Exagamglogene Autotemcel a Rolling Review for the Potential Treatment of Sickle Cell Disease and Transfusion-dependent Beta Thalassemia.

Benzinga ·  Sep 27, 2022 11:16
CRISPR Therapeutics shares are trading higher after the company and Vertex Pharmaceuticals announced the FDA granted exagamglogene autotemcel a rolling review for the potential treatment of sickle cell disease and transfusion-dependent beta thalassemia.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment